

A

- Abacavir
 case study, 359
 drug labeling and, 448
 infectious diseases and, 317
 pharmacist and, 465
 pharmacodynamics of, 198
 toxicogenomics of, 367
- ABC transporters, 153-154
- ABCB1, 154-158, 160-161, 258, 263, 314
- ABCC transporter family, 161-168
- ABCC1, 161-162
- ABCC2, 162-163
- ABCC3, 163
- ABCC4, 163
- ABCC5, 163
- ABCC6, 166
- ABCC8, 407-409, 410-411, 414, 446
- ABCC11, 166-167
- ABCG2, 167-168
- Acamprosate, 394
- Acarbose, 421-422
- Access issues, 474
- Accreditation Counsel for Pharmacy Education, 461
- Accuracy, 72
- ACE inhibitors, 194-195, 200, 230, 232-233, 296
- Acenocoumarol, 222
- Acetaminophen, 112
- Acute lymphoblastic leukemia, 270-271
- Acute myeloid leukemia, 271
- Adams, Patti W., 375-403
- Addiction disorders, 299, 375-403
- Adipokinins, 421
- ADRB2, 445
- Adverse drug event (ADE), 107, 108, 111
- Adverse drug reaction (ADR)
 drug metabolism and, 107, 108, 111, 119, 123, 130, 133-134, 136
 ethics and, 472-473
 increased incidence of, 197-201
- Aerosolized tobramycin, 345
- Afatinib, 204, 269
- Age dilemma, 476-477
- Agranulocytosis, 293, 294
- Albuterol, 331
- Alcohol addiction, 192
 pharmacotherapy for, 393-394, 396
 treatments, 299
- Alectinib, 205
- Alert, 453, 457-458
- Alkylating agents, 268
- Allele, 3, 8
 detection of, 59, 70-71, 74, 92, 94
 discrimination, 59, 68, 70-72, 74-75, 88, 90-92, 94
 frequency calculations for, 34
 genetics and, 19, 20, 22, 28-30, 32, 34-47, 49, 52-53
 methodologies, 59, 60, 70-75, 85-94, 96-97
 respiratory diseases and, 327, 336-338, 343, 346
 -specific amplifications, 92-93
- Allele-specific oligonucleotide (ASO) hybridization, 59, 74, 90-91
- Allelic drift, 38
- All-trans retinoic acid (ATRA), 271
- Alpha-glucosidase inhibitors, 406, 421-422
 gene polymorphisms and, 425
- Alzheimer's disease, 201, 296
- American Academy for Study of Liver Diseases, 322
- American College of Cardiology, 228
- American College of Medical Genetics working group, 475
- American Heart Association Foundation, 228
- American Hospital Formulary Service Drug Information*, 461
- Americans with Disabilities Act, 479
- Amino acid, 25
- Amiodarone, 243-244
- Amitriptyline, 285
- Analytical specificity, 71-72
- Ancillary information, 467-468, 470, 473, 475-477, 480-481
- Anderson, Keri C., 453-466
- Angiotensin II receptor blockers, 230, 232-233
- Angiotensin-converting enzyme inhibitors, 10, 170
- Annealing, 65, 66
- Ansong, Miriam A., 491-498
- Anthracyclines, 167, 263
- Anthracenediones, 263
- Antiarrhythmic agents, 124, 242-244, 444, 473
- Antibiotics, metabolomics and transporters affecting, 313-314
- Anticoagulants, 217-223
- Anticonvulsants, 157
- Antidepressants, 121, 124, 157, 160-161, 290-292, 300
- Antiepileptic drugs, 163, 294
- Antihistamines, 157
- Antihypertensives, 124
- Antineoplastic response, 196
- Antiplatelets, 217-223
- Antipsychotics, 124, 199-200, 292-294, 473
- Antiretroviral hypersensitivity, 317-320
- Antiretroviral resistance testing, 318
- Antiretroviral therapy, 192, 200-201
- Antisense strand, 24
- Apixaban, 223
- Apyrase, 78
- AQP2 gene variant, 420

Arachidonate 5-lipoxygenase gene (ALOX5), 337-338

Arformoterol, 445-446

Arg16Gly, 332-333

Aripiprazole, 285

Aromatase inhibitors, 127

ArrayExpress, 364

Arrhythmia, 215, 242-245

Aspirin, 129-130, 216, 223-224, 274
resistance, 224

Assay(s), 59, 61-62, 70-73, 80, 85-90, 92-97

Asthma, 328-340
case study, 328-329
therapy, 194

Ataluren, 348

Atenolol and warfarin case study, 21

Atomoxetine, 125, 285, 295

Atorvastatin, 216, 236, 240, 241

Ataxia telangiectasia mutated gene, 419

ATP-binding cassette (ABC), 9, 152

Attention-deficit hyperactivity disorder, 295

Atypical antipsychotic, 283, 293

Autonomy, 467, 469, 471, 474, 481

Autosomal chromosome, 34-35

Autosome (autosomal), 19, 34

Azathioprine, 134, 368
case study, 6

Azithromycin, 314, 345

B

Bacteria, 310-312

Bacterial resistance, 310-312

Barefield, Kimberly L., 405-433, 437-451

Basal insulin, 406

BChE enzyme, 131-132

Beclomethasone dipropionate, 334

Beneficence, 467, 469, 470, 474, 483

Beta agonists/theophylline, 345

Beta-blocker(s), 10, 157, 185, 187, 190-191, 230-232, 444

Beta-Blocker Evaluation in Survival Trial, 231

Beta-2 adrenergic receptor agonists, 330, 331-333

Beta-adrenergic receptors, 189-190

Beta-adrenoreceptor antagonists, 473

Bevacizumab, 204

Biguanide, 417
gene polymorphisms and, 425

Binding motif, 327, 337

Bioactivation, 127

Biofilm, 327, 342

Biological fitness, 38

Biomarker(s), 3, 12-13
disease states and, 201
medications and, 285-290
pharmacodynamics and, 183, 184, 201-202
toxicogenomics and, 364-365, 367, 369
valid. *See* Valid biomarkers

Biotransformation, 111-113

Bipolar disorder, 294-295

Bradykinin-mediated cough, 200

Breast cancer, 272-273

resistance protein, 263

Brexiprazole, 285

Bridge amplification, 67, 68-69, 81

Brivaracetam, 285

Bromocriptine, 406

Bronchiectasis, 327, 341-342

Buccal epithelial cells collection, 63

Bucindolol, 231

Budesonide, 334

Buprenorphine, 394, 396

Bupropion, 128, 395, 396

Burkitt's lymphoma, 34

C

Cabozantinib, 204

Caffeine, 117

Calcium channel blockers, 157

Camptothecin derivatives, 167

Camptothecins, 263

Canagliflozin, 423

Cancer/carcinoma, 202-205, 257, 259, 272
biology, 258
chemoprevention, 257, 261, 268-269, 272, 274
chemotherapy, 257, 260-261, 266, 276
genetics, 269-274
syndromes, 274

Candidate gene study, 257, 262

Capecitabine, 129

Carbamazepine, 198, 284, 286, 298, 300, 367

Cardiovascular diseases, 215-256, 439-440, 443-445
valid biomarkers for, 440

Carvedilol, 120, 125, 444, 445

Case-control studies, 52

Celecoxib, 120

Cell
differentiation, 276-277
surface receptors, 189

Centers for Disease Control and Prevention, 95

Centers for Medicare & Medicaid Services (CMS), 72, 95

Central nervous system disorders, 283-308, 447
drug targets for, 192-193
valid biomarkers for, 442

Ceritinib, 205

Cerivastatin, 14

Cetuximab, 203, 204, 273

CFTR protein, 341-342
drugs for, 345-350
dysfunction classification for, 343
mutations of, 343-344

Chain termination sequencing, 75-76

Chemiluminescence, 74

Chemoattractant, 327, 342

Chemotherapeutic agents, 263-268

Children, research on, 483-484

Chlorpropamide, 407, 408

Chromatid, 19, 31

Chromosomal aberrations, 34

Chromosome, 19, 20, 22, 28-29, 32-34, 39-40, 43

Chronic lymphocytic leukemia, 271

- Chronic myelogenous leukemia, 272
- Ciclesonide, 334
- Cimetidine, 124
- Ciprofloxacin, 314
- Cisapride, 198, 199
- Citalopram, 286
- Clarification of Optimal Oral Anticoagulation through Genetics, 221-222
- Clarithromycin, 199, 313
- Clearance, 127
- Cleavage-based assays, 86-87
- Cleavase/FRET (fluorescence resonance energy transfer), 87, 88
- Clinical coordinator, 456
- Clinical decision support, 453, 456, 461
- Clinical interventions, 453, 456, 457-459
- Clinical Laboratory Improvement Amendment (CLIA) of 1988, 72, 95
- Clinical pharmacist/pharmacy specialist, 456
- Clinical Pharmacogenetics Implementation Consortium, 115, 223, 284, 365-366
- Clinical practice, 477, 480-481, 491-498
- Clinical protocols, 453, 457
- Clinical validity, 437
- Clobazam, 286
- Clomipramine, 286
- Clopidogrel, 472
 - cardiovascular treatment with, 216, 224-229
 - drug labeling of, 444
 - drug metabolism for, 121, 122, 124, 128
- Clozapine, 116-117, 286
 - induced agranulocytosis, 294
- Cobimetinib, 205
- Cocaine, 131
- Codeine, 126-127, 299
 - case study, 110
- Coding region SNPs, 30
- Colorectal cancer, 273
- Combinatorial probe-anchor ligation, 83-84
- Communitarianism, 472
- Copy number variant polymorphisms, 19
- Copy number variation, 257, 262
- Corticosteroids, 345
- Corticotrophin-releasing hormone receptor-1, 335
- Cox, Arthur G., 151-181
- COX inhibitors, 195
- Crizotinib, 205
- Crossover recombination, 40
- CTRB1, CTRB2, 422
- Culturing, 310-311
- Cyclic reversible chain termination, 81
- Cyclophosphamide, 117-118, 168, 264, 268
- Cyclosporine, 157
- CYP1A2, 115-117, 300, 339
- CYP2A6, 392
- CYP2B6, 117-118
- CYP2C subfamily, 118-122
- CYP2C8, 421
- CYP2C9, 118-121, 413-414, 416, 439-440, 443-444
- CYP2C10, 121-122
- CYP2C19, 122-124, 413-414, 444, 447, 448
- CYP2D6, 5, 8, 29, 96, 124-128, 444-445
 - case study, 62
- Cysteinyll LT receptor genes, 338
- Cystic fibrosis, 201-202, 328, 340-350
 - case study, 329
- Cystic Fibrosis Foundation, 341
- Cytochrome P (CYP), 267-268
 - isoforms of, 111
 - phenotypes, characteristics of, 114-115
- Cytochrome P450 (CYP450), 29, 107
 - CNS and, 292
 - drug labeling and, 439-440, 443-444
 - drug metabolism and, 111-112, 115-129
 - isoforms in drug metabolism, 109
 - Phase I and, 115-117
- Cytosolic receptors, 193

D

- Dabigatran, 223
- Dabrafenib, 205, 270, 273
- Dapagliflozin, 423
- Dapsone, 313
- Daptomycin, 314
- Darifenacin, 125
- Dasatinib, 269
- Data analysis, 95
- Data interpretation, 61
- Deletion mutation, 33
- Delta opioid receptor, 386-387
- Denaturation, 65, 66
- Deoxyribonucleic acid (DNA), 3, 5, 6
 - amplification of, 64-70
 - clinical practice and, 391, 494
 - diabetes mellitus and, 405, 418
 - genetic basis and, 19-33, 46
 - hematology/oncology and, 258-260, 274-275
 - infectious disease and, 309, 311
 - isolation of, 64
 - microarrays of, 90-92
 - pharmacodynamics, pharmacogenomics of, 183, 184, 187, 196-197, 200, 202
 - pharmacogenomics methodologies and, 60, 61, 71
 - preparation of, 61
 - sample collection, 63
 - sequencing, 75-85
 - sequencing cost of, 97-98
 - structure of, 23

- toxicogenomics and, 357, 360-361, 368
- Dependence, 375, 376, 387
- Desipramine, 128, 286
- Dextromethorphan and quinidine, 286
- Diabetes mellitus, 405-433
early development of, 412-413
- Diagnostic and Statistical Manual of Mental Disorders (5th edition)*, 392
- Diazepam, 286
- Diclofenac, 126, 127
- Differentiation, 258, 277
- Digital droplet PCR, 68
- Digoxin, 111, 158-160, 244
- Dihydrocodeine, 299
- Dihydromorphine, 299
- Dipeptidyl peptidase-4 inhibitors, 422
- Dipropionate, 334
- Direct oral anticoagulants, 223
- Director of pharmacy, 456
- Discrimination reaction, 74-75
- Disease states, 201
- Distributive justice, 467, 470-471, 474
- Disulfiram, 396
- Diuretics, 230, 233-234
- Divalproex sodium, 286
- Docetaxel, 168, 268
- Dosing algorithm, 215, 220-221, 241
- Doxepin, 287
- Doxorubicin, 168
- DPD, 447
- DPP-4 inhibitors, 406
- DPYD, 129-130
- Drug
addiction treatments, 299
development, 13
discovery, 493
efficacy, 12
efflux pumps, 262-263
information, 460-461
interactions, 12-13
labeling, 437-451, 459-460
response, 195
- Drug information specialist, 456
- Drug metabolism
biotransformation and, 111-113
cancer and, 261-263
pharmacogenetics of, 107-150
- Drug metabolism, biotransformation, 111-113
- Drug-metabolizing enzymes, 108-109, 115-116, 365
- Drug target, 106, 183, 184-189, 192-196, 198-203
- Drug transport pumps, 262-263
- Drug transporters, 417
- Dual antiplatelet therapy, 215, 224
- Dubin-Johnson syndrome, 162
- Duloxetine, 125, 287
- Dutch Pharmacogenetics Working Group, 115
- Dyslipidemia, 200-201, 215, 216, 235, 239
- E**
-
- Efflux pumps, 262-263
- Ehret, Megan J., 283-308
- ELISA, 321
- Elongation, of polypeptide chain, 27
- Empagliflozin, 423
- Emulsion PCR, 68, 69
- Endocrinology diseases, 446
valid biomarkers for, 440
- Endoxifen, 127
- Enhanced Sensitivity Profile Assay, 316
- Enterocyte, 151, 154-156, 162
- Enzyme(s)
-based assays, 85
drug metabolism and, 111
drug targets and, 193-194
-linked immunosorbent assay, 317
- Epidemiologic Catchment Area Study, 292
- Epigenetics, 183, 196-197, 258
- Epilepsy, 297-298
- ePocrates Online Free, 461
- Erlotinib, 204, 269
- Escitalopram, 122, 287
- Esomeprazole, 122, 124, 216
- Estrogen receptors, 193
- Eteplirsen, 287
- Ethical dilemmas, 474-478
- Ethical framework in pharmacy, 471
- Ethics, 467-489
case study, 468
- Ethidium bromide, 67
- Ethinyl estradiol, 112
- Ethnicity
genetic differences and, 48-52
research and, 482
- European Pharmacogenetics of AntiCoagulant Therapy, 222
- Evaluation of Genomic Applications in Practice and Prevention, 292
- Everolimus, 205
- Exon, 19, 24-26, 30, 47
- Extension, 65, 66
- Ezetimibe, 241-242
- F**
-
- Facts & Comparisons*, 461
- Family members, 483
- Farrell, Christopher, 309-326
- Fasting blood glucose, 405, 423
- Felbamate, 298
- Fentanyl, 126, 127
- Fetterman, Andria, 437-451
- Fetterman Jr., James W., 437-451
- 5-fluorouracil (5-FU), 129-130, 197, 262, 264-265
- Flecainide, 243
- Floxuridine, 129
- Fluconazole, 314, 315
- Flunisolide, 334
- Fluorescence, 72-73
- Fluoropyrimidines, 447
- Fluorouracil, 11
- Fluoxetine, 112, 127, 287, 438, 447
and olanzapine, 287
metabolism of, 126

Fluticasone propionate, 334
 Fluticasone/salmeterol, 328-329
 Fluvastatin, 236, 240
 Fluvoxamine, 287
 Folic acid antimetabolites, 266
 Food and Drug Administration (FDA)
 biomarkers and, 13, 136
 CYP2D tests and, 62
 genetic variants testing and, 9
 genotyping test regulation by, 72
 genotyping tests in clinical practice and, 95-96
 pharmacogenomic, genetic tests and, 478
 pharmacogenomic diagnostic tests and, 96-97
 warfarin and, 119
 Forced expiratory volume in 1 second, 327, 332, 337
 Formoterol, 122, 331
 Formulary management, 453, 457
 Fosinopril, 216
 Founder effect, 38
 Fragile X syndrome, 33
 Frameshift mutation, 33
 FRET cassette, 87
 Fungi, 314-315

G

G6PD, 197, 446
 deficiency, 313
 enzyme, 130-131
 Gabapentin, 298
 Gain-of-function allele, 405, 407, 409
 Galantamine, 201, 287
 Gastrointestinal side effects, 198
 Gefitinib, 10, 204, 269
 Gel electrophoresis, 67
 Gemcitabine, 264, 265-266
 Gene expression, 24-25
 profiling, 275-276
 regulation, 27
 Gene function, structure, 22
 Gene therapy, cystic fibrosis, 350
 Gene variation, 27-28
 Genetic association studies, 34-39
 Genetic basis, 19-57
 Genetic code, 20, 25-26, 30
 Genetic drift, 38
 Genetic Information Nondiscrimination Act, 479
 Genetic Risk Assessment of Cardiac Events, 233
 Genetic screening, cancer, 274-275
 Genetic Testing Reference Materials Coordination Program, 95-96
 Genetic variability, 188
 modifying drug response for, 196
 of drug targets, 188-189
 pharmacodynamics and, 9-11
 pharmacokinetics and, 6-9
 Genetic variants, 437, 448
 nomenclature for, 29
 Genetics Informatics of Warfarin to Prevent DVT, 223
 Genistein, 349

Genome, 20, 22, 28-31, 33-34, 39
 Genome-wide association study(ies) (GWAS), 5
 cardiovascular disease and, 223
 genetics and, 20, 28, 46-53
 hematology/oncology and, 258, 262
 Genomic biomarkers, 439
 Genotype, 115
 determination, 70-95
 frequency calculations for, 34-35
 genetics and, 20-21, 28-29, 32, 34-40, 43-52
 in clinical practice, 95-97, 491, 497
 methodologies and, 60-62
 pharmacodynamics, pharmacogenomics, 183, 184, 188, 193-194, 197-200, 202
 screening for, 491
 testing for, 465
 Genotypic tropism assays, 316
 Genotyping assay, 60-61, 95
 components, 61
 HIV and, 319
 Genotyping methods
 advantages, disadvantages of, 73
 summary of, 71
 Gentamicin, 347-348
 Germline mutations, 183, 184, 187
 Glibenclamide, 408, 412
 Gliclazide, 412, 413, 414
 Glimepiride, 407, 412
 Glipizide, 407
 Gln27Glu, 332, 333
 GLP-1 receptor agonists, 406
 Glucagon-like peptide-1 analogs, 422
 Glucocorticoid receptor gene (GR/NR3C1), 335-336
 Glutathione transferases, 9
 Gly16Arg, 445
 Glyburide, 407, 438
 Glycated hemoglobin (HbA1c), 405, 406-409, 411-414, 416-420, 422-425
 GoDART, 418
 database, 411
 Grace, Edward, 309-326
 GRAHF study, 234
 Growth factor inhibitors, 204-205
Guidance for Industry and FDA Staff, 478
Guidance for Industry-Pharmacogenomic Data Submissions, 13

H

H₂-receptor antagonist, 124
 Ha, David, 326-355
 Half-transporter, 167
 Halothane, 201
 Ham, Amy-Joan L., 59-105
 Haplotype(s)
 genetics and, 20, 21, 39-52
 in clinical practice, 45
 pharmacodynamics, pharmacogenomics and, 183-184, 186, 190, 194-196, 206
 HapMap, 152
 Hardy-Weinberg Equilibrium, 35-39

Healthcare cost, 493-494
 Health Insurance Portability and Accountability Act, 479
 Heart failure, 215, 216, 230-234, 244
 Hematologic malignancies, 270-272
 Hematology/oncology, 257-281, 446-447
 valid biomarkers for, 440-442
 Hepatitis C, 320-322
 resistance to therapy, 322-323
 Hepatocyte nuclear factor gene variants, 412
 HER2/neu, 447
 Heroin, 131
 Heterozygote (heterozygous), 20, 28, 37-38
 Heterozygous mutation, 315-316
 Histones, 20, 27
 Homozygote (homozygous), 20, 28, 37-38
 Homozygous mutation, 315
 Host response, 312-313
 HTR2C gene, 293
 Human CYP Allele Nomenclature Database, 8
 Human Genome Organization Gene Nomenclature Committee, 152
 Human Genome Project, 5, 14
 Human Genome Variation Society, 29
 Human immunodeficiency virus (HIV), 315-317, 323
 case study, 310
 resistance testing for, 318-319
 RNA testing for, 317
 therapeutics for, 191-192
 Human leukocyte antigens, 365
 Huntington's disease, 33
 Huston, Sally A., 467-489
 Hybridization, 90-91
 Hydantoin anticonvulsants, 118, 121
 Hydralazine, 132, 230
 Hydralazine/isosorbide dinitrate, 234-235
 Hydrocodone, 126, 127, 299
 Hydromorphone, 126, 127, 299
 Hypersensitivity reactions, 198
 Hypertension, 215, 216, 230-234
 Hypertonic saline (7%), 345

I

ibuprofen, 195, 345
 Ifosfamide, 117-118
 Illumina BeadChip platform, 91-92
 Iloperidone, 287
 Imatinib, 204, 269, 272
 Imipramine, 287
 Immunosuppressants, 157
 Implementation issues, 477-478
 Incidental findings, 475
 Incretin
 effect, 422
 mimetics, 422-423
 Indel, 258, 262
 Individual benefits, 472-473
 Infectious diseases, 309-326, 448
 valid biomarkers for, 443
 Infectious Diseases Society of America, 322

Infinity UGT1A1 Assay, 96
 Inflammation, 195
 Informatics pharmacist, 456
 Informed consent, 480-481, 482-483
 INH therapy, 133
 Inhaled corticosteroids, 333-336
 Initiation factors, 27
 Insertion/depletion polymorphisms, 20, 31, 33
 Insertion mutation, 33
 Insulin
 receptor substrate-1 gene variants, 412
 release, decreased, 412, 422-423
 therapy, 413
 Interferon-based therapy, 322
 International Consortium for Antihypertensive Pharmacogenomics Studies, 235
 International HapMap Project, 46
 International Serious Adverse Events Consortium, 369
 International Verapamil SR/Trandolapril Study, 231
 International Warfarin Pharmacogenetics Consortium, 220, 443
 Interpatient variability
 inhaled corticosteroids and, 334
 leukotriene modifiers and, 336-337
 respiratory diseases and, 327-328, 330-332, 334, 336
 Intron, 20, 47
 Invader assay, 87, 88, 96
 Invader UGT1A1 Molecular Assay, 97
 Inversion mutations, 33
 Investigational drug pharmacist, 456
 Investigational drug service, 453, 456
 Irinotecan
 drug metabolism and, 131, 134
 hematology/oncology and, 263-264, 266-267
 toxicogenomics and, 368
 transport proteins and, 160, 168-169
 Irinotecan case study, 152-153
 Ischemic heart disease, 215, 216, 223, 230-232
 Isoflavone, 327, 349
 Isoflurane, 112
 Isoform, 107, 109, 111, 115-118, 120-125
 Isoniazid, 132, 313, 448
 Isosorbide and hydralazine HCl, 445
 Itraconazole, 315
 Ivacaftor, 202, 329, 346

J

Journals, 496-497
 Justice, 467, 469, 470-471
 ragged edge problem of, 478

K

Kamdem, Landry K., 107-150
 Kappa opioid receptor, 382, 384, 385
 KCJN11, 409-411, 414, 446
 KCNQ1, 414, 422-423

L

Lacosamide, 288
 Lamotrigine, 298
 Lapatinib, 204, 447
 Legal protections, 479-480
 Lenvatinib, 204
 Leukemia, 258, 263-264, 266, 269-272, 276
 Leukotriene A4 hydrolase promoter gene, 338
 Leukotriene modifiers, 336
 Levalbuterol, 331
 Levofloxacin, 314
 Lexicomp, 461
 Ligation-based assay, 87, 89-90
 Linezolid, 314
 Linkage disequilibrium
 genetics and, 20, 21, 38-59
 in clinical practice, 45
 mathematical expression of, 40-41
 measures of, 41-43
 pharmacodynamics, pharmacogenomics and,
 183, 189, 194, 200
 pharmacogenomic association studies of,
 43-44
 plot, 47-52
 transport proteins and, 151, 158
 Lisinopril, 233
 Lithium, 294-295
 Locus, 22
 Lopinavir, 167
 Lorazepam, 111, 112
 Losartan, 120
 Loss-of-function allele
 cardiovascular disease and, 215, 226-227,
 229-230
 diabetes mellitus and, 405, 413, 416
 Lovastatin, 236, 240
 LTC4 synthase promoter gene, 337, 338
 Lumacaftor/ivacaftor combination, 346-347
 Lynch, Launa M. J., 405-433

M

Major depression case study, 290
 Malignant hyperthermia, 201
 Maraviroc, 316, 320
 MassARRAY iPLEX, 94
 MassARRAY system, 74
 Mass spectrometry, 74
 Massively parallel sequencing, 60, 67-68, 72
 MDR1, 157-160
 Medical Devices Amendments of 1975, 95
 Medication safety officer, 456
 Medications with pharmacogenomics data,
 462-463
 Medication-use evaluation, 453, 456, 457
 Medication-use process, 454, 456
 Meglitinide, 414-415, 424
 Meiosis, 31-32, 40
 Melanoma, 273-274
 Melphalan, 170
 Mercaptopurine, 264

MERIT-HF, 231
 Mesolimbic dopamine pathways, 379-381
 Messenger ribonucleic acid (mRNA)
 genetics and, 20, 21, 24-27, 30-31
 hematology/oncology and, 258, 259-260, 275,
 277
 toxicogenomics and, 357, 360
 Metabolic enzymes
 transporter proteins and statins, 236
 Metabolizers, 62
 Metabolomics, 16
 of antibiotics, 313-314
 of antifungals, 314
 of statins, 236
 toxicogenomics and, 357, 360, 364
 viruses and, 319-320
 Metformin, 216, 406, 413, 417-419
 Methadone, 394, 396
 Methodologies, 59-105
 Methotrexate, 11, 162, 172, 264, 266, 270
 Methylphenidate, 295
 Metoprolol, 190-191, 216, 230, 444
 Metronidazole, 313
 Microarray(s)
 analysis of drug compounds for, 36
 Microencapsulated pancreatic enzymes, 345
 Micromedex 2.0, 461
 MicroRNA (miRNA), 95, 258, 259-260, 277
 Microsatellites, 32
 Mitochondrial mixed function oxidases, 107, 111
 Miglitol, 421-422
 Mini satellites, 32
 Minocycline, 314
 Missense mutation, 33, 151, 166
 Mitoxantrone, 167, 263
 resistance protein, 263
 Modafinil, 288
 Molecular haplotyping, 39
 Momary, Kathryn M., 215-225
 Mometasone furoate, 334
 Monogenetic, 357, 365-366, 370
 Monosomy, 34
 Montelukast, 120, 336
 Mood stabilizers, 294-295
 Morphine, 112, 126, 127, 299
 MRPs, 161-162
 MRSA, 311-312
 Mu opioid receptor, 382, 383, 384-385
 Multidrug resistance, 258
 Multidrug resistant 1 (MDR1) gene, 416
 Multiple drug resistance (P-gp), 263
 Multiple sclerosis, 295
 Multivitamin, 345
 Muscular dystrophy, 33
 Mutation, 38
 types of, 32-34

N

N-acetyltransferase, 9
 Naloxone, 394, 396
 Naltrexone, 192, 393-394, 396

NanoTag sequencing, 85
 Narrow therapeutic index (ratio) agent, 107, 110
 Nasal potential difference, 328, 341, 347
 NAT2, 132-133
 Nateglinide, 414, 416
 National Asthma Education and Prevention Program, 329
 National Bioethics Advisory Commission, 481
 National Center for Biotechnology Information, 5, 28, 152
 Entrez system, 29
 National Center for Toxicogenomics, 369
 National Center for Toxicological Research, 370
 National Human Genome Research Institute, 97-98
 National Institute of Environmental Health Sciences, 369-370
 National Institutes of Health (NIH), 5
 National Library of Medicine, 28
 Necitumumab, 204
 Nefazodone, 288
 Nelfinavir, 167
 Neonatal diabetes mellitus, 410-411, 446
 Neuroadaptation, 375, 376, 378, 382, 387
 Neurologic disorders, 295-298
 Neurophysiology, drug dependence, 376-377
 Next-generation sequencing, 77, 274
 Nicotinamide phosphoribosyltransferase NAMPT gene variants, 415
 Nicotine
 acetylcholine receptors for, 390
 addiction treatments for, 299, 395-396
 pharmacodynamics of, 389-390
 pharmacogenomics affecting pharmacokinetics of, 390-392
 reward pathways of, 387-389
 Nintedanib, 205
 Nitric oxide synthase 1 adaptor protein gene, 412
 Nitrofurantoin, 131
 Nitrogen mustard derivatives, 117-118
 Noncoding region SNPs, 30
 Noncoding strand, 24
 Non-maleficence, 467, 469, 470-471, 481
 Nonsense mutation, 33, 151
 Nonsteroidal anti-inflammatory drug (NSAIDs), 131, 118, 269
 Nonsynonymous mutation, 151, 158, 159, 161, 166, 171
 Nonsynonymous single nucleotide polymorphism, 20, 30
 Nortriptyline, 128, 288
 Nucleic acid amplification test (NAAT), 311-312, 317, 321
 Nutrigenomics, 16

O

OATPA, OATPIA2, 168
 Olanzapine, 125
 Oligonucleotide
 hematology/oncology and, 258, 275
 ligation assay for, 87, 89-90
 methodologies and, 60, 65-74, 83, 87, 89-92

Omeprazole, 122, 124
 Oncogenes, 258, 272, 273
 Oncology, 258, 276
 medications, 464
 OncomiRs, 277
 Oncotype DX assays, 275-276
 Ondansetron, 198
 Online Mendelian Inheritance in Man, 152
 Open collaboration, 496
 Open sequencing, 480
 Opioid(s)
 central nervous system and, 283, 298-299
 drug metabolism of, 124
 pathways for, 382-387
 pharmacodynamics, pharmacogenomics of, 192
 transport proteins and, 160-161
 use disorder pharmacotherapy for, 394-395, 396
 Opsonophagocytosis, 328, 342
 Oral antidiabetic therapy case study, 406-407
 Oral glucose tolerance test, 405, 409, 422
 Order sets, 454, 457
 Osimertinib, 204
 Outpatient settings, 461-465
 Oxcarbazepine, 288
 Oxidative stress, 197
 Oxycodone, 125, 127-128, 299
 Oxymorphone, 126, 127, 299

P

P2Y₁₂ inhibitors, 229-230
 Paclitaxel, 268
 Pain, 298-299
 Pantoprazole, 124
 Parkinson's disease, 296-297
 Paroxetine, 127, 198, 288
 Paternalism, 469
 Patient counseling case study, 454-455
 Pazopanib, 205
 PCG-restriction fragment length polymorphism (PCR-RFLP), 85-86
 PDES inhibitors, 349-350
 Peak expiratory flow, 328, 332, 338
 Peptide nucleic acid-FISH, 314
 Performance improvement project, 454-457
 Perindopril, 233
 Perphenazine, 288
 Pertuzumab, 204, 447
 P-glycoprotein (ABCB1), 9, 154-158, 258, 263, 320
 transporter, 314
 PharmGKB, 496
 Pharmacist's role, 453-466, 494-496
 Pharmacodynamics, 3, 5, 6, 183-212
 cancer and, 261-262
 genetic variability and, 9-11
 Pharmacogenetics, 3, 13
 drug metabolism examples of, 113-114
 mindset for, 496
 Pharmacogenetics for Every Nation Initiative, 485
 Pharmacogenomic Biomarkers for Drug Labeling, Table for, 439

- Pharmacogenomics, 3, 4-5, 437
 benefits, challenges of, 15
 education and, 11-13
 evidence for, 477
 generally, 3-17
 program for, 454-458, 465
 studies, Hardy-Weinberg Equilibrium in, 37-39
 variants for, 7
- Pharmacogenomics Research Network, 5
- Pharmacogenomics variants, 7
- Pharmacokinetics, 3, 4
 cancer and, 261
 genetic variability and, 6-9
- Pharmacy and therapeutics committee, 454, 456-457
- Pharmacy manager, 456
- Phase I metabolism, 7
 enzymes in, 115-132
 reactions in, 111-112
- Phase II metabolism
 conjugation reactions in, 111, 112-113
 enzymes in, 132-136
 reactions in, 7, 9
- Phenobarbital, 298
- Phenotype
 drug metabolism and, 115
 genetics and, 20, 28, 30, 34-35, 37-38, 40, 43, 46-47, 52-53
 pharmacodynamics, pharmacogenomics and, 183, 184, 187, 196
- Phenotype assays, 316
 HIV and, 318, 319
- Phenprocoumon, 222
- Phenytoin, 118, 284, 288, 297, 298
- Philadelphia chromosome, 34, 272, 447
- Pimozide, 288
- Pioglitazone, 420, 421
- Pirbuterol, 331
- Point mutation, 3, 4
- Polygenic, 357, 365-366, 370
- Polymerase chain reaction (PCR), 64-69, 258, 311
- Polymerase-mediated sequencing by synthesis, 81, 83
- Polymorphism(s)
 drug metabolism and, 115-116
 generally, 3, 5, 8-9, 10-11, 14
 in clinical practice, 491
 indirectly modulating drug response, 195
 infectious diseases and, 309, 312
 methodologies and, 60, 62, 70-75, 78-81, 85-87, 90-92, 94-96
 multiple agent dependence and, 378-379
 nicotinic acetylcholine receptors and, 390
 nonopioid substance addiction and, 386
 opioid pharmacodynamics and, 384-386
 pharmacodynamics, pharmacogenomics and, 184-201, 206
 Phase I enzymes and, 129-131
 types of, 29-32
 variants in, 258, 261-263, 265, 267-268, 274, 277
- Poor metabolizers, 300
- Population stratification and admixture, 52-53
- Posaconazole, 315
- Postprandial insulin levels, 415
- PPARG gene variants, 420
- PPIs, 121, 124
- Pramlintide, 406
- Prasugrel, 124, 229-230, 444
- Pravastatin, 168, 236, 240, 445
- Pre-arrhythmic medication effects, 244
- Primaquine, 129, 366-367
- Primary prevention, 215, 269
- Primer extension, 60, 71, 74, 78, 92, 94
- Procainamide, 242
- Promoter, 491
- Propafenone, 242-243, 444
- Propranolol, 230, 444, 445
- Prostate cancer, 273
- Protease inhibitors, 157
- Protein nanopores, 84-85
- Protein synthesis, 27
- Proteomics, 3, 16, 357, 360, 364, 370
- Proton-pump inhibitors, 8
- Protriptyline, 289
- Psychiatric disorders, 447
 extreme anxiety case study, 438
 valid biomarkers for, 442
- Purine analogs, 264
- Purine bases, 23
- Pyrazinamide, 448
- Pyrimidine bases, 23
- Pyrogram, 78
- Pyrosequencing, 78-81

Q

- QT interval, 244-245
 prolongation, 198
- Quinidine, 444

R

- Race
 genetic differences and, 48-52
 research and, 482
- Racial profiling, 477
- Ragged edge problem, 478
- Raloxifene, 267
- Ramucirumab, 204
- Randomized controlled trials, 477-478
- Rapid metabolic phenotypes, 113
- Reaction product detection, 72, 74
- Recombinant human DNase, 345
- Recombination process, 40, 41
- Regulations, 479-480
- Remission, 283
- Repaglinide, 414-415, 416
- Reporter probe, 87
- Reproducibility, 72
- Research, 481-484
 agendas, 484-485
- Resources, 496-497

- Respiratory disease, 327-355, 445-446
 valid biomarkers for, 440
- Response, 283, 284
- Restriction enzymes, 60, 85-86
- Restriction sites, 60
- Reward pathway(s), 377-378
 activation of, 382
 for nicotine, 387-389
- Ribavirin-based therapy, 322
- Ribonucleic acid (RNA), 491
 genetics and, 20, 21-27, 30
 hematology/oncology and, 258, 259-260, 264, 266, 275
 HIV testing and, 317
 structure of, 23
- Ribosomes, 27
- Rifampin, 313, 314, 448
- Rights theory, 472
- Risks, 474
- Risperidone, 128, 289, 447
- Rivaroxaban, 223
- Rivastigmine, 201
- RNASeq, 95
- Roberts, Ali, 107-150
- Roche AmpliChip CYP450 test, 62, 96
- Rofecoxib, 195
- Rolling circle amplification (RCA), 68, 69
- Rosiglitazone, 120, 420, 421
- Rosuvastatin, 236, 240, 241
- Rotello, Rocco J., 491-498
- Ryanodine receptor, 201
- S**
-
- Salmeterol, 331, 445
- Salmeterol Multicenter Asthma Research Trial, 330-331
- Sanger sequencing, 75-76
- Sarcomas, 258, 259, 272
- Schizophrenia, 292-293
- SEARCH study, 236
- Secondary prevention, 215, 240, 269
- Selective estrogen receptor modulators, 267
- Selective serotonin reuptake inhibitors (SSRIs), 10
 central nervous system and, 284, 292
 drug metabolism and, 128
 ethics and, 473, 478
 pharmacodynamics, pharmacogenomics and, 192
 transport proteins and, 160
- Sensitizers, 417
- Sequencing
 by ligation, 83
 by synthesis, 78, 82
 in clinical practice, 491-493, 495, 497
- Serotonin
 receptors, 10, 198-199
 transporter, 192, 290-291
- Shah, Samit, 19-57, 183-212, 327-355
- Short tandem repeat (STR) polymorphisms, 20, 32
- Sibutramine, 199
- Signal transduction systems, 189
- Silent mutation, 33
- Simvastatin, 236, 237
- Single Molecule Real Time technology, 84
- Single molecule sequencing, 84-85
- Single nucleotide polymorphism (SNP), 20
 anticancer agents and, 158-159
 coding region for, 30
 database for, 152
 diabetes mellitus and, 405, 419, 421-423
 ethics and, 475
 generally, 4, 5, 6, 9
 hematology/oncology and, 258, 262, 274, 276
 in clinical practice, 492
 infectious diseases and, 309, 313
 noncoding region for, 30-31
 pharmacodynamics, pharmacogenomics and, 184, 189-190, 192, 194-197, 199-200
 tagging, 43, 45
 transport proteins and, 151, 152, 174
- Single-base extension, 94-95
- Single-stranded primers, 65
- 6-mercaptopurine, 9, 134, 264, 270, 368
- 6-thioguanine, 9, 264
- SLCO1A2, 168
- SLCO1B1, 168-169, 414-415
- Smith, Helen E., 357-373
- SNaPshot kit, 94-95
- Societal benefits, 473-474
- Sodium 4-phenylbutyrate, 349
- Sodium butyrate, 348-349
- Sodium-glucose co-transporter type 2 inhibitors, 423
- SOLID system, 83
- Solid-phase bridge amplification, 68, 69
- Solute carrier (SLC), 152
 organic anion transporter family member 2B1
 gene, 339
 proteins, 168-173
 SLC1A1, 169
 SLC15 family, 170-171
 SLC17A8, 171
 SLC18A2, 171
 SLC19A1, 171-172
 SLC22A1, 172, 417-418, 426
 SLC22A2, 172, 418-419
 SLC22A4, 173
 SLC22A5, 173
 SLC22A9, 173
 SLC22A12, 173
 SLC28, 173
 SLC29, 173
 SLC30A8, 415-416
 SLC47A1, 419
 SLC6 family, 169-170
 SLC7 family, 170
 SLC8 family, 170
 superfamilies, 9
- Somatic cell mutations, 184, 187-188, 202-203
- Sorafenib, 204
- Specialty areas, 464
- Splice site variants, 259, 265, 267

Stanford University (PharmGKB), 152
 Star allele, 107, 113
 Start codon, 25
 Statin(s), 10, 157, 235-241
 efficacy of, 238-239
 -induced myopathy, 235-238
 Statistical haplotyping, 39-40
 ST-elevation myocardial infarction case study, 216-217
 Stent thrombosis, 216, 224, 227-228
 Stigma, 475-476
 Stimulants, 295
 Study protocol, 454, 456, 458
 Substance abuse disorder, 376, 392-393
 Substitutions, 33
 Succinylcholine, 111, 112, 201
 Sulfa-based agents, 131
 Sulfamethoxazole, 199
 Sulfamethoxazole-trimethoprim, 313-314
 Sulfonylureas, 118, 406-407, 410-414, 424, 446
 Sunitinib, 204
 Surrogate marker, 216, 224
 Syncytiotrophoblast, 151, 162, 165
 Synonym codons, 25
 Synonymous mutation, 151, 159, 171
 Synonymous single nucleotide polymorphism (SNP), 20, 30

T

Table of Pharmacogenomic Biomarkers in Drug Labeling, 365
 Tacrine, 201
 Tagging SNP, 43, 45
 Tamoxifen, 127-128, 193, 264, 267, 269, 276-277
 case study, 259-261
 Taq polymerase, 65
 TaqMan, 92, 93-94
 Tardive dyskinesia, 199, 293-294
 Target sequence, 64
 Taxanes, 268
 TCF7L2, 411, 415, 423
 Template
 preparation, 64-70
 strand, 24
 Temsirolimus, 205
 Terfenadine, 199
 Tertiary prevention, 269
 Testing, economic impact of, 448-449
 Tetrabenazine, 289
 Theophylline, 330, 339-340
 Therascreen EGFR RGQ PCR kit, 97
 Thiazide diuretics, 230, 233-234
 Thiazolidinediones, 406, 419-421
 Thioguanine, 134, 264
 Thiopurine, 134, 447
 Thiopurine methyltransferase, 5, 9, 259, 262
 Thioridazine, 289
 Thompson, Todd A., 257-281
 Thr164Ile, 332, 333
 Thromboembolic disorders, 197
 Throughput, 60, 67, 85

Thymine, 129
 Ticagrelor, 229-230, 444
 Tillery, Erika E., 375-403
 Tobacco use disorder
 case study, 376
 pharmacotherapy, 395, 397
 Tolazamide, 407
 Tolbutamide, 407, 412
 Tolerance, 375, 378, 382
 Topiramate, 298
 Topoisomerase I inhibitors, 266-267
 Topotecan, 263
 Toxicogenetics, 358-360, 364, 368, 371
 Toxicogenomics, 16, 357-373
 Toxicogenomics Research Consortium, 369-370
 TPMT, 133-134, 447
 Tramadol, 126, 127, 299
 Trametinib, 205
 Transcript profile databases, 364
 Transcription, 24, 26
 Transcription factor T-bet, 335
 Transcriptomics, 358
 Transfer RNAs, 26-27
 Translation, 26-27
 Translocations, 33-34
 Transport proteins, 151-181
 Transporter(s), 151-156, 160-174, 365
 localizations, polymorphisms of, 164-166
 Trastuzumab, 203, 204, 273, 447
 Treatment resistance, 472
 Triazole antifungals, 314-315
 Tricyclic antidepressants, 128, 284
 Trimipramine, 289
 Trisomy, 34
 Tumor suppressor genes, 259, 271, 277
 Type 1 diabetes mellitus, 406, 422-423
 Type 2 diabetes mellitus, 406-424, 426
 Typical antipsychotic, 283, 293
 TZDs, gene polymorphisms and, 425

U

Ubiquitination, 328, 343
 UGT1A+28, 160
 UGT1A1, 134-136, 445
 Uracil, 129

V

Valganciclovir, 170
 Valid biomarkers, 437-451
 Valproic acid, 289, 298
 Valsartan, 120
 Vandetanib, 204
 Varenicline, 397
 Variable number of tandem repeat polymorphisms.
 See Short tandem repeat polymorphisms
 Veatch, Robert M., 471
 Vemurafenib, 205, 270, 273
 Venlafaxine, 125, 289, 447
 Virus(es), 315-316
 metabolomics and transporters, 319-320

VKORC1, 444
Vogel, Frederick, 4
Voriconazole, 314-315
Vortioxetine, 290

W

Ware, Kenric B., 453-466
Warfarin, 10, 11
 atenolol case study, 21
 cardiovascular disease and, 217-223
 drug labeling of, 439, 443
 drug metabolism of, 108, 118
 ethics and, 472
 tagging SNP to predict dosage, 45
 toxicogenomics and, 366
 transport proteins and, 185-186, 188
Warfarin response, 193-194
Web-based resources, 497
Webster, Kathy D., 19-57, 183-212
Weight gain, 199-200, 293
Weston, G. Scott, 107-150
WFS1, 423

Whole blood collection, 63
Whole genome sequencing, 4
Whole saliva sample, 63
Wild type
 genetics and, 20, 28-29, 32
 methodologies of, 60, 70, 75, 85, 87, 89, 92,
 94, 96
Withdrawal, 375, 376, 378, 382, 387
Wolfram syndrome, 423

X

X^2 -test of genotype data, 37
Xenobiotic, 107, 111
Ximelagatran, 198

Z

Zafirlukast, 336
Zdanowicz, Martin M., 3-17
Zero Mode Waveguide, 84
Zidovudine, 167
Zileuton, 10, 194, 336